Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Human Rho D Immune Globulin
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PRIVIGEN Granted Orphan-Drug Designation
Details : CSL Behring advances Ig clinical trial program to address need in treating serious autoimmune disease.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 11, 2020
Lead Product(s) : Human Rho D Immune Globulin
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?